A scientific study on the cellular and genetic effect of the treatment used for malignant lymphomas.

Phase 1

• Conditions: Diffuse Large B-Cell Lymphoma, Mantlecell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma, B-CLL if Rituximab is used as part of treatment.; MedDRA version: 18.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864; MedDRA version: 18.0Level: LLTClassification code 10036712Term: Primary mediastinal large B-cell lymphoma NOSSystem Organ Class: 100000004864; MedDRA version: 18.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864; MedDRA version: 18.0Level: LLTClassification code 10016934Term: Follicular predominantly small cleaved cell lymphoma (Working Formulation) NOSSystem Organ Class: 100000004864; MedDRA version: 18.0Level: LLTClassification code 10026799Term: Mantle cell lymphoma NOSSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-002677-30-DK
• Lead Sponsor: Professor Hans Erik Johnsen, MD, DMSc, Department of Haematology, Aalborg Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08-09
• Last Update Posted: 23 July 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Any patient who have
1) planned treatment with R-CHOP or different R-chemotherapy for a haematologic disease in accordance with current guidelines at Aalborg Hospital.
2) age above 18 yrs.
3) ability to undestand and will to sign the informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 42
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 42

Exclusion Criteria

Any patient who
1) due to adverse reactions have their regular treatment cancelled.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified